Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03620643
Title Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Royal Marsden NHS Foundation Trust

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

diffuse gastric cancer

Advanced Solid Tumor



Crizotinib + Fulvestrant

Age Groups: adult | senior
Covered Countries

No variant requirements are available.